GLP – 1 Therapies: From promise to practice

As GLP-1 therapies gain traction, their safe and effective integration into India’s diabetes care ecosystem will depend on clinical evidence, affordability and long-term monitoring

GLP-1 therapies are becoming an increasingly important part of the conversation around diabetes and obesity management in India. The entry of lower-cost semaglutide options has brought greater attention to their potential, while clinicians are considering their role beyond blood glucose control and weight reduction. Their use, however, raises important questions around patient selection, affordability, treatment continuity and the monitoring needed to support long-term outcomes. 

India’s clinical context adds another dimension. Body composition, metabolic risk at lower BMI levels, dietary patterns and differences in access to specialist care all influence treatment decisions. As more patients and clinicians consider these therapies, the focus is shifting towards identifying who is most likely to benefit and how treatment can be integrated into routine diabetes and obesity care. 

Moving beyond weight loss 

The expanding discussion around GLP-1 therapies reflects a broader understanding of metabolic health. Their role cannot be assessed through weight reduction alone, particularly when patients may have multiple conditions that influence treatment choices. 

Dr Rajiva Gupta, Senior Consultant, Internal Medicine and Diabetes, CK Birla Hospital, Gurugram, says, “I think we are moving from seeing these medicines mainly as ‘sugarlowering drugs’ to understanding their wider role in diabetes and obesity care. For the right patient, they can help with blood glucose and weight, and some therapies have shown benefits for cardiovascular , liver and kidney outcomes too.” 

This broader role also makes individual assessment essential. Treatment decisions need to account for the patient’s health risks, existing conditions and ability to sustain therapy, rather than being driven by the expectation of rapid weight loss.

Dr Vimal J. Pahuja, Associate Director, Department of Medicine, Metabolic Physician & Diabetologist, Dr L H Hiranandani Hospital, Mumbai, says, “The discussions concerning GLP-1 drugs have shifted. Patients want to know whether they can use these medications for weight loss, and clinicians are thinking about using them as part of the management of diabetes and obesity in general, and their complications, in particular. 

The key questions here are: “What health condition do you want to improve?” A person who has diabetes, obesity and cardiovascular disease should be discussed in a completely different way than an individual interested in weight loss before getting married. Selection should include indications, benefits, nutritional status and treatment persistence.” 

The Indian population also presents specific considerations around body composition and metabolic risk. A single measure such as BMI may not fully capture the risk profile of an individual, making clinical assessment and appropriate treatment goals important. 

Dr Phulrenu Chauhan, Consultant, Endocrinology, P. D. Hinduja Hospital & Medical Research Centre, Mahim, says, “GLP-1s are no longer a niche, expensive option in India. With generic semaglutide now in the market, they are becoming part of everyday practice, which is welcome but needs some discipline. We need to choose the drug by the patient’s main problem, whether that is glycaemia, weight, fatty liver, kidney disease or cardiovascular risk, rather than prescribing the same thing to everyone.” 

Greater availability, therefore, does not remove the need for careful prescribing. The clinical decision has to consider the intended benefit, the patient’s wider health status and the support needed alongside medication. 

Dr Bhawna Attri, Consultant-Endocrinology, Sarvodaya Hospital says, “GLP-1 receptor agonists are gaining attention in India for their role in managing type 2 diabetes and obesity. These therapies help regulate blood glucose, improve satiety and support weight loss, mak – ing them an important option for selected patients who need additional support beyond conventional treatment. Some agents have also demonstrated cardiovascular and kidney ben – efits in specific patient populations. However, their use must be guided by clinical need rather than the expectation of rapid weight loss.” 

For clinicians, the challenge is to distinguish appropriate medical use from the growing perception of these medicines as quick weight-loss solutions. That distinction also depends on how well patients under – stand the purpose and limits of treatment. 

Dr Himika Chawla, Senior Consultant- Endocrinology, PSRI Hospital, New Delhi, says, “GLP-1 drugs provide an additional tool for managing di – abetes 2 and obesity among other conditions. However, I want to emphasise that these medications should not be viewed as a means for weight loss or normalising blood glu – cose levels alone. For a number of selected patients, they can also reduce the probability of some heart and kidney risks. The key is to understand who actually needs them and whether they are suitable for that person’s overall health.” 

Dr Shubhra Gupta, Sr. Con – sultant-Physician, RG Hospi – tals, Delhi, East Of Kailash, says, “These therapies may be particularly useful for patients with type 2 diabetes who also have obesity or are unable to achieve their treatment goals with existing medications. However, lifestyle modification, dietary counselling and physical activity must remain central to treatment.” 

The scale of diabetes and obesity in India makes access to appropriate treatment an important consideration. Yet adoption also depends on awareness, patient acceptance and the capacity of clinicians to explain treatment choices. 

Dr Vyankatesh Shivane, Consultant Diabetologist & Metabolic Physician, Depart – ment of Endocrinology, Jaslok Hospital & Research Center, Mumbai, says, “India, Considered as Diabetes Capital of the world with prevalence at rise. Equal number of pre diabetics who are in wait list to become diabetic in future. 50 per cent still unknown about their diabetes status. A typical Indian Type 2 diabetes young onset even in third decade or some – times second decade of life, poorly controlled, having huge belly fat (abdominal obesity), overweight or obese and more prone for complications to diabetes at younger age.” 

The adoption question is also about whether treatment decisions are based on a patient’s overall condition and long-term goals. Prescribing should include a discussion of potential benefits, possible side effects and the practical implications of continuing treatment. 

Dr Sandeep Kharb, Associate Director– Endocrinology, Asian Hospital, Faridabad, says, “GLP-1 medicines have provided yet another valuable tool in the management of type 2 diabetes and obesity However, the decision to pre – scribe them should go beyond a patient’s blood sugar levels or weight. We need to consider at the person’s overall health, existing medical conditions, treatment history and long-term goals. These medicines can definitely help a patient who is appropriate for treat – ment, but it is not a medicine for everyone One important aspect of treatment is setting realistic expectations.” 

The availability of more treatment options also brings the question of how evidence translates into practice. The clinical context in India, including metabolic risks at lower BMI levels, needs to inform the way patients are assessed and followed up. 

Dr Piyush Lodha, Endocri – nologist, Ruby Hall Clinic, Pune, points to the South Asian phenotype and body composi – tion as an important area re – quiring further evidence: 

The South Asian Phenotype and Body Composition: Indian patients frequently exhibit the “thin-fat” phenotype—higher body fat percentage and visceral adiposity alongside lower skeletal muscle mass, often at lower BMI thresholds. Global trials emphasize overall weight loss, but local evidence is needed to track whether rapid GLP-1-induced weight loss leads to clinically significant muscle loss (sarcopenic obesity) in Indian cohorts. 

The question of who benefits most also extends to patients whose metabolic risk may not be apparent from weight alone. Treatment selection needs to reflect the patient’s health profile rather than a uniform threshold. 

Dr David Chandy, Director of Endocrinology and Diabetology, Sir H. N. Reliance Foundation Hospital, Mumbai, says, “For instance, in India, use has gone beyond lowering of glucose levels in type 2 diabetes and now includes management of chronic obesity based on availability of new options and generic semaglutide. The selection must include consideration of approved uses, obesity complications, cardiovascular and renal risk, nutritional status and affordability. Cardiovascular and renal benefits depend on specific medications and study groups. Tirzepatide, which is considered while GLP1 medications are mentioned, is a dual GIP/GLP-1 receptor agonist.” 

The wider availability of therapies must be matched by appropriate medical assessment and counselling. This is particularly important when patients approach treatment with expectations shaped by public discussion of weight loss. 

Dr Himanshu Sharma, Senior Consultant, Endocrinology, diabetes and metabolism, Yashoda Medicity, says, “GLP-1 therapies are changing how we approach type 2 diabetes and obesity, but the conversation in India is now moving beyond weight loss to who should receive these medicines, for how long and with what support. With semaglutide generics entering the market, access is expanding, but easier availability should not be confused with suitability for everyone.” 

Monitoring beyond the weighing scale 

Starting therapy is only the beginning of the clinical process. Dose escalation, tolerability, nutritional intake and changes in body composition all need attention during follow-up. The aim is to assess whether the treatment is meeting its intended goals without compromising other aspects of health. 

Dr Rajiva Gupta says, “Starting the medicine is only one part of the job. We need to explain how the dose is increased, what side effects to expect, when to contact the doctor and why follow-up matters.” 

A structured monitoring plan can help clinicians identify problems early and adjust treatment when required. It also gives patients a clearer understanding of what to expect during different stages of therapy.

Dr Pahuja says, “Follow-up should be more complicated than recording kilogram loss. A patient may be happy with quick weight loss, but he/she may have poor food intake, lack of energy, and problems with constipation. All this information should play an important role in the dose increase. Baseline evaluation should include metabolic parameters, renal function, medications, nutrition, and eye diseases. In the course of therapy, check out hydration, gastrointestinal symptoms, glucose levels, and physical abilities. Sometimes, doses of insulin and sulfonylureas need to be modified. Clinics require a good contact and recall system, and nutritional counseling between visits.” 

 

Nutrition and muscle preservation are particularly relevant when treatment results in substantial weight loss. Monitoring should consider whether patients are maintaining adequate dietary intake and physical function, rather than relying on changes in body weight alone. 

Dr Chauhan says, “In Asian Indians, BMI understates the problem: we carry more visceral fat and often start with less muscle, so follow waist and body composition and push protein and resistance exercise to protect lean mass. The cardio metabolic and renal benefits are real, but most of the hard outcome data comes from Western trials, and we should be honest about that.” 

These considerations place greater importance on followup systems that extend beyond the prescribing consultation. Clinicians need to review the patient’s response, address side effects and coordinate support where required. 

Dr Attri says, “Patients prescribed GLP-1 therapies require structured monitoring, beginning with a comprehensive assessment of their medical history, weight, HbA1c, blood glucose levels and other relevant health parameters. Treatment is generally initiated at a low dose and increased gradually, depending on the specific medicine, tolerability and clinical response. Follow-up visits should assess gastrointestinal symptoms, hydration, nutritional intake, weight changes, glycaemic control and medication adherence.” 

Regular review also helps patients understand when to seek advice and why unsupervised changes to treatment can be problematic. The need for continuing medical support becomes particularly relevant when patients experience side effects or have difficulty maintaining the treatment plan. 

Dr Chawla says, “In my view, one of the biggest concerns is that people sometimes focus on the medicine itself and overlook the care that needs to go along with it. These drugs can affect appetite and digestion, and some patients may experience nausea, vomiting or other stomach-related problems. When someone starts eating much less, we also need to make sure they are still getting enough nutrition. This is why regular consultations matter. Patients should be able to discuss what they are experiencing and get proper guidance instead of trying to manage the treatment on their own.” 

Clinical assessment also needs to take account of existing medicines and health conditions. The requirements may differ between patients, making a standardised but individualised approach to care important. 

Dr Shivane says, “In case of GLP-1 therapy, not one rule for all. To start GLP-1 therapies a complete clinical assessment is must by endocrinologists, physicians and cardiologist. It must be ensured that patient does not have any existing or possible pancreatic disease, gall bladder disease. Patient’s pre-existing diabetic medicines like sulfonylureas or Insulin needs dose modification to avoid low blood sugars (hypoglycemia). Proper diet assessment and dietary modifications are required. Patient must be counseled about potential side effects of GLP-1 therapy and its mitigation.” 

Long-term follow-up also needs to assess the patient’s experience of treatment and whether the plan remains practical. Expectations around the duration and cost of therapy should be discussed before treatment begins.

Dr Kharb says, “Prescribing a medicine without discussing the patient’s ability to pay and continue the medicines long term can result in the same adherence challenges. It is the responsibility of the prescribing doctor to explain the duration, cost, risks and benefits of treatment before starting it. We also need more Indian evidence to understand long term implications of these therapies among various subgroups of our heterogeneous population, considering lifestyle and other metabolic risk factor differences. Research that reflects these differences can help doctors make more informed treatment decisions.” 

The availability of trained clinicians and follow-up support is another part of the equation. Patients need access to medical guidance through dose escalation and subsequent reviews, particularly when there are concerns about tolerability or other health risks. 

Dr Chandy says, “The initial assessment needs to identify weight, waist circumference, HbA1c, kidney function, medications, medical history and intentions of pregnancy. It is important to start treatment with low dose and slowly increase it. The follow up during the dose increasing should include assessment of gastrointestinal side effects, hydration, intake of food and glucose with adjustments of insulin or sulfonylurea when needed. For patients with retinopathy, eye follow up will be required. At first, monthly follow ups should be done and then quarterly follow ups should assess metabolic effect, nutrition, strength and adherence.” 

A care pathway must also address changes in appetite, nutrition and physical function as treatment progresses. Such monitoring is particularly relevant when substantial weight loss may affect muscle mass or nutritional status.

Dr Sharma says, “Prescribing a GLP-1 therapy is only the beginning of treatment. The real clinical work lies in monitoring how the patient responds, managing side effects and ensuring that weight loss does not come at the cost of muscle mass or nutritional health. Along with blood sugar and weight, follow-up should assess gastrointestinal symptoms, hydration, dietary intake and physical function. Patients may need individualised nutritional guidance, adequate protein intake and resistance exercise to help preserve muscle, particularly during substantial weight loss.” 

The evidence gap around treatment duration and discontinuation is also important for clinical practice. Patients may face interruptions for financial or personal reasons, and clinicians need better information on how these changes affect metabolic outcomes. 

Dr Lodha identifies postdiscontinuation outcomes as an area requiring more study: Post-Discontinuation Outcomes and Treatment Durability: Because long-term therapy is frequently interrupted in realworld Indian settings due to cost or personal preference, there is minimal evidence on structured step-down strategies. Research is needed to understand rebound hyperglycemia, weight regain, and metabolic changes once treatment stops.

The experience of patients after discontinuation is closely connected to the question of whether they can sustain treatment over time. Clear communication about the likely duration of therapy and the possibility of weight regain can help patients make informed decisions. 

Dr Rajiva Gupta says, “Despite reduced costs for certain brands and greater availability of lower-cost options, cost remains a major barrier, especially because treatment may need to continue for a long time. Additionally, patients need medicines with reliable action and safety and a clinician who can guide treatment.” 

Evidence, affordability and the care ecosystem 

The growing use of GLP-1 therapies also highlights the need for more evidence from Indian patients. International trials provide important information, but clinicians need to understand how outcomes translate across different body compositions, diets, health profiles and patterns of healthcare access. 

Dr Pahuja says, “What does India have in terms of evidence that speaks to practical prescribing dilemmas? What occurs when patients discontinue therapy due to expense? How do older individuals with low muscle reserves fare? What nutritional interventions are successful for vegetarians that don’t get adequate amounts of protein? More extended Indian studies would investigate therapy continuation, body composition, muscle strength, complications, and quality of life. Loss of weight will not answer the question of whether a person’s health improved. Multicentre registries would cover those endpoints in various practice environments.” 

Research that reflects routine clinical practice could help clarify which patient groups benefit most, how treatment is sustained and what happens when it is interrupted. It could also inform decisions on monitoring and resource allocation across different care settings.

Dr Chauhan says, “Most of what we know about GLP-1s comes from trials in which South Asians were barely represented, so we are partly extrapolating when we prescribe them here. We have very little long-term Indian data on how long the benefit lasts, what happens to muscle and bone, and how safe these drugs are over the years, including the pancreatitis and thyroid questions.” 

The need for local evidence extends to the practicalities of prescribing and continuing treatment. Research should account for differences in access, affordability and the ability to maintain follow-up beyond specialist centres. 

Dr Attri says, “Although international clinical trials have established the effectiveness of GLP-1 therapies for specific indications, more India-specific evidence is needed to guide their long-term use. Research should examine outcomes across India’s diverse population, including variations in body composition, dietary patterns, disease severity, socioeconomic status and associated health conditions. Long-term real-world studies are particularly important to understand treatment persistence, weight regain after discontinuation, adverse effects, cardiovascular and kidney outcomes, and the cost-effectiveness of these medicines in routine practice.” 

Dr Shubhra Gupta says, “An important evidence gap is the limited availability of longterm, real-world Indian data across diverse patient groups. Differences in dietary patterns, genetic and metabolic risk, healthcare access and the high prevalence of multiple metabolic conditions make locally relevant research essential. Studies should examine longterm effectiveness, cardiovascular and kidney outcomes, treatment persistence, nutritional consequences, cost-effectiveness and the risk of weight regain after discontinuation.” 

For clinicians, this evidence can support decisions about patient selection, treatment response and the point at which a change in management may be needed. It can also help build more practical guidance for patients who cannot continue treatment. 

Dr Chawla says, “We also need to learn more about how these medicines work for Indian patients over the long term. People have different eating habits, health conditions and financial circumstances, all of which can affect their experience with treatment. More information from our own population would help doctors understand these differences and make better decisions. I believe the focus should be on treating the patient as a whole rather than relying on medication alone. Along with the right treatment, people need practical advice on food, physical activity and managing their condition in everyday life. Doctors also need to keep reviewing whether the treatment is working and whether it continues to meet the patient’s needs.” 

Cost remains a central challenge because treatment may need to continue over an extended period. The initial price of a medicine is only one consideration; consultations, investigations, nutrition support and follow-up can also affect whether a patient is able to remain on treatment. 

Dr Shivane says, “Current evidence based medicine, has provided enough evidence about potential scope of GLP-1 in Indian scenario. Many of the marketed GLP-1 therapies and few which are in pipeline have undergone through clinical research in Indian subset of patients. It has been proven better safe and effective approach in managing Type2 diabetes and obesity. More awareness is required in India about ideal body weight, Body mass Index etc. This must be educated from school itself. India needs broad scale policies for awareness across urban as well as rural sectors. Healthy living is everyone’s right and healthy lifestyle must be educated to everyone. More research would be helpful from urban, semi urban and rural population for cost effectiveness of GLP-1 therapies.” 

The broader healthcare system will need to support appropriate prescribing, follow-up and referral. Integration into diabetes care should also make it easier for patients to access relevant expertise without treating medication as a standalone solution. 

Dr Kharb says, “GLP-1 treatments should be integrated into a comprehensive weight management plan. This demands inter-professional cooperation of clinicians, dietitians and others, coupled with well-established protocols for follow-up. The treatment should be tailored to the patient, and the emphasis should be on health outcomes rather than simply weight loss.” 

Access and affordability need to be considered alongside safety and prescribing standards. As the range of available products grows, clinicians and patients need clear information about approved uses and the practical requirements for sustained treatment. 

Dr Chandy says, “Cost may be an impediment since the treatment will continue for years. Less expensive products may increase access, however, sustainable treatment involves cost-effective consultations, testing, and nutritional support. Lack of equal access to specialists, unequal counseling and the expectation of quick weight loss may reduce adherence. Injection fears and misinformation may also deter patients from the treatment. 

Nausea and vomiting need anticipatory counseling; severe abdominal pain persistently calls for urgent investigation. The prescription of this medication should adhere to the product-specific contraindications, which include personal and family history of medullary thyroid carcinoma or MEN2 if indicated.” 

The need for continuity becomes particularly important when treatment is interrupted because of cost, side effects or other barriers. Care pathways should address these situations rather than focusing exclusively on treatment initiation.

Dr Sharma says, “In India, we need care pathways that extend beyond the prescribing consultation. This includes planned follow-ups, medication reviews and access to dietitians and diabetes educators. As more patients explore these therapies, affordability and continuity of care will also matter. Patients should understand that stopping treatment can lead to weight regain, and that long-term management needs to be discussed from the outset. The priority is not simply to initiate treatment, but to make it safe, sustainable and clinically meaningful.” 

Affordability and appropriate prescribing are also linked to the regulatory and clinical responsibilities of healthcare professionals. Clear guidance can help clinicians distinguish medically appropriate use from treatment driven primarily by cosmetic expectations. 

Dr Lodha highlights the importance of regulatory compliance and patient safety, “OffLabel Prescribing and Regulatory Compliance: The popular demand for weightloss therapies has raised concerns regarding off-label use and informal dispensing without full medical evaluation. Under Indian healthcare regulations, including the Drugs and Cosmetics Act & Rules and the National Medical Commission (NMC) Registered Medical Practitioner (Professional Conduct) Regulations, 2023: Approved Indications: Clinicians must clearly distinguish between globally discussed indications and locally approved labeling by the Drugs Controller General of India (DCGI) for specific molecules and formulations. Documentation & Informed Consent: Prescribing off-label or for cosmetic weight reduction without documented medical evaluation, baseline screening, and informed patient consent increases medicolegal risk in cases of adverse events.” 

Guidelines and care pathways can help translate evidence into everyday clinical decisions, including patient eligibility, dose escalation, monitoring and referral. They also need to reflect the practical realities of long-term treatment and the range of professionals involved in patient care. 

Dr Rajiva Gupta says, “Guidelines should make the practical decisions clearer: who is likely to benefit, how to initiate treatment, how to increase the dose, what to monitor and when to seek specialist advice. They should also explain what to discuss if a patient cannot afford treatment or needs to stop it. We need a team approach where primary care physicians, specialists , dietitians, and diabetes educators can support the patient.” 

The next stage of adoption will depend on whether the healthcare system can combine appropriate patient selection with accessible, consistent and coordinated care. GLP-1 therapies may offer meaningful benefits for selected patients, but sustained outcomes require attention to the wider factors that shape diabetes and obesity management. 

The clinical objective is not simply to make treatment more widely available. It is to ensure that patients receive it for the right reasons, understand what it involves and have the support needed to manage their health over time. 

 

The way forward 

The next phase of GLP-1 therapy adoption in India will depend on how effectively the healthcare system moves from initial access to sustained, clinically supervised care. Wider availability must go hand in hand with appropriate patient selection, regular monitoring, clear guidance on treatment duration and support for maintaining outcomes over time. For clinicians, the priority will be to individualise treatment decisions based on each patient’s metabolic profile, associated conditions and response to therapy, while helping patients understand that medication is part of a broader care plan. 

As evidence grows and treatment options evolve, stronger clinical guidance, continued research and better patient education will be essential to ensure that the promise of GLP-1 therapies translates into meaningful, long-term outcomes for India’s diabetes care ecosystem. 

 

 

 

 

Kalyani.sharma@expressindia.com

journokalyani@gmail.com

 

diabetes and obesity managementGLP-1 receptor agonistsGLP-1 therapies in IndiaGLP-1 treatment guidelinessemaglutide generics
Comments (0)
Add Comment